A clinical trial finds that the anticoagulant apixaban, which has been prescribed to help COVID-19 patients recover, is ineffective and in rare instances dangerous.
Bats that experience food shortages due to climate change and habitat loss end up roosting in urban settings, where they shed more of the deadly Hendra virus.
The Scientist Creative Services Team in collaboration with Thermo Fisher Scientific | 1 min read
Edward Emmott will discuss mass spectrometry approaches to understand proteolysis during viral infection and their use in developing targeted strategies for COVID-19 treatment.
Researchers say they’re abandoning the project in its current form—one of several that aims to induce what’s known as mucosal immunity against SARS-CoV-2.
Recent studies have lent support for a variety of hypotheses explaining the debilitating symptoms affecting millions of people after SARS-CoV-2 infection.
The Scientist’s Creative Services Team | 1 min read
Richard Webby and Edward Hutchinson discuss influenza viruses—the development of new strains, how they mediate virulence, and their threat to human society.
Launched with a $172 million philanthropic donation and funds from the state of Victoria, the Melbourne-based research institute aims to construct drug discovery platforms to speed the introduction of new therapies.
The immunizations are designed to target the latest Omicron subvariants, and are only authorized for people who have already received their primary vaccinations.
![several blue office chairs sit empty in a carpeted room, with a paper sign saying "Vaccination centre welcome" pasted on the white wall above. ](https://cdn.the-scientist.com/assets/articleNo/70641/aImg/48209/empty-chair-article-image-t.jpg "several blue office chairs sit empty in a carpeted room, with a paper sign saying "Vaccination centre welcome" pasted on the white wall above. ")
